Pregnancy Reduces COVID-19 Vaccine Immunity Against Novel Variants

Maclaine A. Parish[1], Jaiprasath Sachithanandham[1], Lizeth Gutierrez[2], Han-Sol Park[1], Anna Yin[1], Katerina Roznik[2], Patrick Creisher[1], John S. Lee[1], Laura A. St Clair,[1] Annie Werner[1], Catherine Pilgrim-Grayson[4], Lea Berhane[5], Hana Golding[6], Patrick Shea[1], Katherine Fenstermacher[7], Richard Rothman[7], Irina Burd[8], Jeanne Sheffield[9], Andrea L. Cox[1,2], Andrew Pekosz[1,2,7], and Sabra L. Klein[1,2*]

[1]W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

[2]Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA

[4] Division of Rare Diseases and Medical Genetics; Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine; Office of New Drugs; Center for Drug Evaluation and Research; U.S. Food and Drug Administration, Silver Spring, MD, USA

[5]Division of Clinical Policy, Office of New Drug Policy, Office of New Drugs; Center for Drug Evaluation and Research; U.S. Food and Drug Administration, Silver Spring, MD, USA

[6]Division of Viral Products, Center of Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

[7]Department of Emergency Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA

[8]Department of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD, USA

[9]Department of Obstetrics and Gynecology, Johns Hopkins School of Medicine, Baltimore, MD, USA

*Address correspondence to Sabra L. Klein, (410)955-8898, sklein2@jhu.edu

Abstract

Pregnant women are at heightened risk for severe outcomes from many infectious diseases, including COVID-19. Pregnant women were not included in the initial COVID-19 vaccine clinical trials which might have contributed to low rates of vaccine uptake among them (15% or lower). We explored the serological and cellular responses to COVID-19 mRNA booster vaccines (i.e., ancestral and BA.5) in pregnant and age-matched, non-pregnant females to identify how pregnancy affects immunity against vaccine viruses in addition to novel variants. Blood was collected from participants prior to and 3-5 weeks post booster vaccine. Post-vaccination antibodies from pregnant women were less cross-reactive to non-vaccine antigens, including XBB1.5 and JN.1, than antibodies from non-pregnant females. Antibodies from non-pregnant females showed strong correlations between IgG1 and FcR binding and greater IgG1:IgG3 ratios and live-virus neutralization against all variants. In contrast, antibodies from pregnant women had lower IgG1:IgG3 ratios and neutralization and greater antibody-dependent NK cell cytokine production and neutrophil phagocytosis, particularly against variants. CD4+ T cells from pregnant patients exhibited reduced polyfunctionality, with IFNγ+ monofunctional dominance. In contrast, among non-pregnant women, CD4+ T cells displayed greater polyfunctionality, with more IL-21+ cells. Pregnancy may reduce the breadth, composition, and magnitude of humoral and cellular immunity, particularly in response to novel variants.

Introduction

Pregnant women faced significant morbidity and mortality during the COVID-19

pandemic, with an elevated risk for severe outcomes [1-3]. From the onset of the pandemic

in early 2020 to December 2022, there were 24,203 cases of COVID-19 among pregnant

women in the United States with 2,043 fatalities [4]. This 8.4% mortality rate is significantly

higher than that of the general population (0.061%), reflecting the elevated risk for disease

outcomes in pregnancy. Pregnant women also were more likely to require hospitalization

and invasive ventilation from acute SARS-CoV-2 infection than non-pregnant women [3, 4].

Adverse pregnancy and neonatal outcomes were an additional concern, as SARS-CoV-2

infection has been associated with preeclampsia, stillbirth, NICU admission, and preterm

birth in women [1, 5-9] and mouse models [10].

The Centers for Disease Control and Prevention [11] and the American College of

Obstetricians and Gynecologists (ACOG) recommend vaccination during pregnancy to

provide optimal protection against SARS-CoV-2 for both the mother and fetus [12]. Data

from November 2021 show vaccination rates among pregnant women (45.1%) were

significantly lower than that of non-pregnant people (64.9%) [13]. Vaccination rates among

pregnant women have since fallen precipitously, and remain lower than the general

population, with less than 15% of pregnant women vaccinated in the 2023-2024

vaccination season [14]. This decline in vaccine uptake is particularly concerning given that

other vaccines offered during pregnancy, such as influenza and Tdap, show higher coverage

rates (47.4% and 59.6%, respectively) [15, 16]. Despite a favorable benefit of administering

COVID-19 vaccines during pregnancy [17-19], low vaccine uptake may be a result of greater

vaccine hesitancy in this population [20-25].

While vaccination is the best preventative strategy to reduce the severity of COVID-

19 outcomes [17, 26], existing evidence suggests pregnant women mount dampened

immune responses to vaccination, highlighting the need for deeper immunological

assessments [27]. Previous studies of COVID-19 vaccines in pregnant women have

focused on placental antibody transfer following vaccination during pregnancy,

demonstrating the benefits of maternal vaccination in protecting newborns and infants

from severe infection [28-30]. While several studies have aimed to compare the antibody

landscape induced by vaccination during pregnancy with those in non-pregnant women

[31], to date, the effects of pregnancy on cross-protection against circulating variants in

addition to vaccine antigens have remained unexplored.

Using systems serology, we can broadly and deeply characterize the antibody

landscape in response to COVID-19 vaccination. By employing this systematic and

comprehensive approach, we can gain insight to shape future vaccine development and

public-health campaigns by understanding the protective immune response generated by

vaccination [32]. Combining functional assays and systems serology methods, we show

that the breadth and diversity of antibody generated by vaccination and polyfunctionality of

spike-specific memory CD4+ T cells are reduced during pregnancy.

Methods

Study Design

Pregnant women were enrolled into mRNA vaccine studies at the Johns Hopkins Maternal

& Fetal Medicine Clinic (IRB 00246472) (n=7 pregnant) during the 2022-2023 vaccination

season. Pregnant women were contacted at clinical visits or via phone to determine

interest and eligibility. Women were eligible if they planned to receive an mRNA COVID

booster vaccine (Pfizer of Moderna) during weeks 32 through 36 of pregnancy, and consent

to maternal blood collection before and after receipt of the booster vaccine. Patients who

had already received an initial dose(s) of the vaccine were still eligible to enroll. Throughout

recruitment, 232 pregnant women were approached to participate in this study. Ninety-one

patients were initially interested while only 14 enrolled in the study. Of these, 7 completed

the study. For non-pregnant female comparators, samples were obtained from age-

matched adult female healthcare workers who were recruited during the 2022-2023

influenza vaccine enrollment period by fliers, emails, and announcements about the

annual vaccination program and were able to self-enroll upon receipt of the influenza

vaccine at the Johns Hopkins East Baltimore hospital (IRB00288258) (n = 13 non-pregnant).

Demographic information is detailed in **Table 1**. Of the vaccinees enrolled, 13 age-matched

non-pregnant females received the COVID-19 booster vaccine during the same vaccination

season and had pre- and post-vaccination blood samples available. Plasma and peripheral

blood mononuclear cells were obtained prior to and one month after receipt of mRNA

booster vaccines from pregnant and non-pregnant females. Plasma was used to assess

antigen-specific immunoglobulin isotype responses and live virus neutralizing antibody

responses, in addition to the crystallizable fragment (Fc) receptor affinity and non-

neutralizing antibody functions. Cryopreserved PBMCs were used for flow-cytometry

analyses.

Cells and Viruses

VeroE6-TMPRSS2 cells were obtained from the cell repository of the National

Institute of Infectious Diseases, Japan, and were grown in complete medium consisting of

Dulbecco's modified Eagle's medium (DMEM) (Gibco, Thermo Fisher Scientific),

containing 10% fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific), 1 mM glutamine

(Invitrogen, Thermo Fisher Scientific), 1 mM sodium pyruvate (Invitrogen, Thermo Fisher

Scientific), 100 U/mL penicillin (Invitrogen, Thermo Fisher Scientific), and 100 µg/mL

streptomycin (Invitrogen, Thermo Fisher Scientific). Cells were incubated at 37°C in a

humidified incubator with 5% CO_2.

Ancestral (hCoV-19/USA/DC-HP00007/2020; B.1, GISAID EPI_ISL_434688), BA.5

(hCoV-19/USA/MD-HP32103-PIDCNSQVGY/2022, GISAID EPI_ISL_15013106), XBB.1.5

(hCoV-19/USA/MD-HP40900-PIDYSWHNUB/2022, GISAID EPI_ISL_16026423), and JN.1

(hCoV-19/USA/MD-HP49672-PIDDVSVURS/2023, GISAID EPI_ISL_18623285) variants of

SARS-CoV-2 were isolated in VeroE6-TMPRSS2 cells plated in 24-well plates as previously

described [33]. The consensus sequence of the virus isolate did not differ from the

sequence derived from the clinical specimen. The infectious virus titer was determined on

Vero-E6-TMPRSS2 cells using a 50% tissue culture infectious dose (TCID50) assay as

described [34].

Microneutralization assays

Plasma neutralizing antibodies [35] were determined as described for SARS-CoV

and modified for SARS-CoV-2 as described [36]. Two-fold dilutions of plasma, starting at a

1:20 dilution, were made using incomplete medium (IM) - Dulbecco's modified Eagle's

medium (DMEM) (Gibco, Thermo Fisher Scientific), containing 1 mM glutamine (Invitrogen,

Thermo Fisher Scientific), 1 mM sodium pyruvate (Invitrogen, Thermo Fisher Scientific), 100

U/mL penicillin (Invitrogen, Thermo Fisher Scientific), and 100 μg/mL streptomycin

(Invitrogen, Thermo Fisher Scientific). Infectious virus was added to the plasma dilutions at

a final concentration of 1×10^3 TCID50/mL or 100 TCID50 per 100 μL. The plasma-virus

solution was incubated at room temperature for 1 hour, and 100 μL of each dilution was

added to 1 well of a 96-well plate of VeroE6-TMPRSS2 cells in hextuplicate. The cells were

incubated for 6 hours at 37°C with 5% CO_2. The inoculum was replaced with fresh IM, and

the cells were incubated at 37°C with 5% CO_2 for 3-4 days until cytopathic effect (CPE) is

evident in the no serum controls. The cells were fixed by the addition of 100 μL of 4%

formaldehyde for at least 4 hours at room temperature, and then stained with naphthol

blue-black overnight. The nAb titer was calculated as the highest serum dilution that

eliminated the CPE in 50% of the wells (NT50), and the AUC was calculated [37, 38].

Antigen-bead coupling

Antigen-specific isotyping and Fc-receptor binding affinity were multiplexed using a

Luminex Intelliflex in a 384-well format. Antigens used in this panel are as follows:

ancestral spike (S) and nucleocapsid (N) protein, BA.5, XBB.1.5, and JN.1 spike proteins

were obtained through the National Cancer Institute Serological Sciences Networks

(SeroNet) for COVID-19 [39]. Each antigen was coupled to unique bead MagPlex bead

regions (Luminex). Briefly, beads were activated by activation solution consisting of

activation buffer (0.1M NaH2PO4; pH 6.2), 50mg/mL 1-ethyl-3-[3-dimethylaminopropyl]

carbodiimide (EDC), and 50mg/mL Sulfo-NHS (N-hydroxysulfosuccinimide). Activated

beads were coupled to 25ug of antigen in coupling buffer (0.05M MES; pH 5.0). Activated

coupled beads were blocked with blocking buffer (PBS 1X, 0.1% BSA, 0.02% Tween-20,

0.05% sodium azide; pH 7.4), washed with washing buffer (PBS 1X, 0.05% Tween-20) and

stored at 4°C in PBS.

Luminex serological assays

Serum was diluted 1:25 and was incubated with bead solution (20 µL of each bead

region in 20 mL of Luminex Assay Buffer: PBS 1X, 0.1% BSA, 0.05% Tween-20). This

protocol was followed for isotyping (IgM, IgG [IgG1-4], and IgA [IgA1-2]) and binding to the

following Fc receptors (FcRs): FcγRIIA-R, FcγRIIA-H, FcγRIIb, FcγRIIIA-V, FcγRIIIA-F,

FcγRIIIB, FcRn, and FcαR (Duke Vaccine Institute – Protein Production facility). Following

incubation, plates were placed on a magnet and washed with Procartaplex Wash Buffer

(ThermoFisher). Each assay plate was then incubated with 45 µL of secondary antibody

diluted in Luminex Assay Buffer. Isotypes were identified by PE-conjugated antibodies

(Southern Biotech) and FcR proteins were biotinylated using BirA biotin-ligation kit (Avidity)

at least one day prior and coupled to PE-Streptavidin (BioLegend). Following incubation

with secondary antibody, plates were placed on a magnet and washed. Beads were

resuspended in Procartaplex Wash Buffer before running on the Luminex Intelliflex.

Samples were run on FlexMap 3D Low with a DD range of 7000-1700. For each assay, the

MFI of secondary antibody-conjugated to PE, or FcR protein-conjugated to PE for each

bead region was measured on the Luminex Intelliflex to quantify antigen-specific

immunoglobulin isotypes and FcR responses in each sample at 0- and 28-days post

vaccination [40].

Antibody-dependent complement deposition (ADCD)

178   Serum (1:15 dilution) was added to the MagPlex antigen coated beads. Plates were

incubated, placed on a magnet, and washed 3 times with 1% BSA. Lyophilized Low-Tox

Guinea Pig Complement (Cedarlane) was reconstituted in ice-cold dH2O and diluted 1:25

in Gelatin Veronal buffer with Mg^{2+} & Ca^{2+} (GVB++) (Boston Bio). Diluted complement

protein was added to each well followed by incubation at 37C. IgG goat anti-guinea pig C3

(MP Biomedicals) was diluted 1:500 in 0.1% BSA and added to each well. After incubation,

Donkey-anti goat IgG secondary antibody-PE (ThermoFisher) was diluted 1:200 in 0.1% BSA

and added to each well. Beads were resuspended in 0.1% BSA and run on the Luminex

Intelliflex.

Antibody-dependent NK-cell cytotoxicity (ADNK)

188   Natural killer (NK) cells were isolated from donor blood. Whole blood was

centrifuged through a Ficoll gradient to harvest PBMCs and NK cells isolated from PBMCs

using the MagniSort™ Human NK-cell Enrichment Kit (ThermoFisher) with adjustment to a

final concentration of 1.5 x 10^6 cells/mL in R10 medium, and IL-15 (1 ng/mL, Abcam) was

added and incubated overnight. Plates were coated with 3 mg/mL antigen (ancestral, BA.5,

XBB.1.5, and JN.1 spike proteins – SeroNet), blocked with 5% BSA, washed, and dried

before adding serum (1:100 dilution). Inhibitor cocktail (2.5 µL CD107a-PeCy5 (BD

Bioscience - BDB555802) + 0.5 mL BFA (Millipore Sigma) + 1 µL Golgi Stop (BD Bioscience)

+ 9 mL R10 medium) was added to each well, incubated, and surface staining cocktail (1 µL

CD3-Pacific Blue (BD Bioscience - BDB558117) + 1mL CD56-PE-Cy7 (BD Bioscience -

BDB557747) + 1 mL CD16-APC-Cy7 (BD Bioscience - BDB557758) + 7 mL PBS) is added to

a V-bottom 96-well plate. NK cells were transferred to the V-bottom 96 well plate with pre-

added surface stain cocktail and incubated. Cells were pelleted, supernatant removed,

and Perm A (ThermoFisher) was added to each well. Cells were washed and Intracellular

staining cocktail (1 mL IFNγ-APC (BD Bioscience -) + 1 mL MIP1-B-PE (BD Bioscience -

BDB550078)   + 48 mL Perm B (ThermoFisher) was added to each well. Plates were washed,

cells were resuspended in PBS and run on a Symphony A3 through the Bloomberg Flow

Cytometry and Immunology Core. Gating strategy as follows: NK cells- CD3-, CD16+,

CD56+ with reported cell populations including IFNγ+, CD107a+ and MIP-1β + NK cells.

Antibody-dependent neutrophil phagocytosis (ADNP)

208   Antigens (ancestral, BA.5, XBB.1.5, and JN.1 spike proteins – SeroNet) were

biotinylated with the BirA biotin-ligation kit (Avidity) and coupled to FluoSpheres™

NeutrAvidin™-Labeled Microspheres, 1.0 µm, yellow-green fluorescent (505/515)

(ThermoFisher). Antigen was combined with Neutravidin beads and incubated. Serum was

diluted 1:100 in PBS and incubated with antigen coated beads. During incubation, cells

were isolated from donor blood. Whole blood was collected into CPT tubes and centrifuged

at 1000 rpm for 30 min. Granulocytes were collected from below the density gradient. Cells

were suspended 1:10 in ACK Lysis buffer and incubated at RT for 5 min to lyse red blood

cells. Cells were washed and resuspended in 10 mL of PBS. Plates were washed with PBS,

200 mL of neutrophil solution (5 x 10^6 cells/plate) was added to each well, incubated,

spun at 500g for 5 min, and cells were resuspended in extracellular staining solution (0.5

mL APC CD66b (BioLegend - 305117) + 19.5mL PBS / well) and incubated for 15min

covered with foil at RT. After staining, plates were washed and resuspended in 4% PFA to fix

cells, washed and resuspended in PBS. Plates were run on the Attune NxT flow cytometer.

Gating on CD66b+ cells (neutrophils) followed by bead+ neutrophils, stained with APC.

Data are reported as a PhagoScore, calculated as (% bead-positive neutrophils) *

(geometric MFI of each cell) [41].

Antibody-dependent cellular phagocytosis (ADCP)

THP-1 cells, a human monocytic cell line, were plated 2.5 x 10^4 per well. Cells were

grown in suspension and diluted with warm R10 medium. Following immune complex

formation, assay plates are washed with PBS and centrifuged at 2000g for 10 min. The THP-

1 cells were added, and plates were incubated O/N at 37°C. THP-1 cells were fixed,

washed, and resuspended in PBS. Plates are run on the Attune NxT flow cytometer. Gating

included bead+ single-cells stained with APC, representing THP-1 cells that have

phagocytosed bead. Data are reported as a PhagoScore, calculated as (% bead-positive

neutrophils) * (geometric MFI of each cell) [42].

Ex vivo flow cytometry staining

PBMCs were used to assess phenotype and function of immune cells. For broad

immune cell phenotyping (BIP), cells were stained for viability with Biolegend Live/Dead

Zombie NIR Fixable Viability Dye (423105) and BD Biosciences Fc Block™ (564219). Cell-

surface staining was performed with surface-antibody-cocktail mix (**Supplementary

Methods Table 1A**). Cells were fixed and permeabilized with a 1X Fixation/Permeabilization

buffer from eBioscience FoxP3/Transcription Factor Staining Buffer Set. Intracellular

staining was performed with intracellular antibody-cocktail mix (**Supplementary Methods**

Table 1B). Cells were resuspended in 1% paraformaldehyde and run on the 4-laser (16UV-

16V-15B-8R) Cytek Biosciences Aurora spectral flow cytometer. Data were exported for

further analysis in FlowJo for analysis (**Supplemental Figure 4**).

Intracellular cytokine-flow cytometry staining was used to assess antigen-specific

cytokine production and T-cell phenotypic and functional profiles. Cryopreserved PBMCs

were thawed, rested, and cultured overnight with 1 mg/mL peptide pools consisting of 315

peptides (15-mers with 11 amino acid overlap) spanning the ancestral SARS-CoV-2 spike

protein (JPT Peptide Technologies, PM-WCPV-S-1) or a DMSO (unstimulated) control. After

overnight incubation, cells were washed and stained for flow cytometry as described for

BIP with the following variation: staining for viability was with Invitrogen Live/Dead Fixable

Blue Dead Cell Stain (L34962) and with T-cell panel surface and intracellular cytokine-

antibody cocktails (**Supplementary Methods Table 2A-B**). For ICS, data were processed

using biexponential transformation and exported for further analysis in FlowJo to assess

cytokine-producing, antigen-specific T cells (**Supplemental Figure 5**). Polyfunctionality of

these T cells was analyzed with Pestle v2.0 and SPICE 6 v6.1.

Statistical analyses

GraphPad Prism v10.1 was used to perform univariate analyses with details about

statistical tests used for each dataset in figure legends. Spearman correlations of systems

serology measures were visualized in heatmaps generated using R v4.2.3 and version

1.0.12 of the package "pheatmap" (https://cran.r-project.org/web/packages/pheatmap

[43]. For ADNP and ADNK assays, data were averaged across two healthy donors. Flow FCS

files were analyzed using FlowJo v10 (10.8.1) software. Gating strategy for BIP and ICS can

be found in **Supplementary Figures 1** and **2**, respectively. ICS and BIP data were exported

from Pestle v2.0 and SPICE 6 v6.1 for further statistical analyses detailed in figure legends.

Results

Pregnancy alters IgG subtype dominance in response to novel variants

Because SARS-CoV-2 nucleocapsid (N) antibodies are not generated by mRNA

vaccines targeted to S protein, this can be used as a proxy for SARS-CoV-2 infection [44],

with recognized limitations [35]. There was no increase in either anti-N IgG **(Figure 1A)** or in

any subclass of IgG **(Supplemental Figure 1A)** in any participants, suggesting that no one

was infected with SARS-CoV-2 during their study enrollment window. However, all

participants had detectable anti-N IgG levels highlighting prior exposure to SARS-CoV-2 in

our cohort. Luminex-bead assays were used to comprehensively characterize the antibody

response generated by vaccination against SARS-CoV-2 vaccine antigens (ancestral and

BA.5 S) and other variants (XBB.1.5 and JN.1 S). COVID-19 boosters induced IgG in both

pregnant and non-pregnant females to vaccine and circulating variants **(Figure 1B)**. Prior to

vaccination, total IgG to ancestral S and BA.5 S was high in both cohorts, as SARS-CoV-2

exposure through infection and prior vaccination is pervasive in the general population

[45]. However, there were distinct differences in the IgG subtype dominating this response.

There was IgG1 subtype dominance among non-pregnant, but not pregnant, females

(Figure 1C-F). While IgG3 contributed to a small proportion of total IgG generated in

response to vaccination, pregnant women were more likely to induce anti-S IgG3 than non-

pregnant females **(Supplemental Figure 1 B-E).**

Pregnancy reduces the cross-neutralizing capacity of antibodies recognizing SARS-

CoV-2 variants

The ratio of IgG1:IgG3 has been shown to be predictive of SARS-CoV-2 neutralization

capacity [46]. Compared with non-pregnant females, pregnant women had reduced

IgG1:IgG3 ratios, particularly to circulating variants, (JN.1 p = 0.02, XBB.1.5 p = 0.05)

demonstrating that the dominant IgG1 response in non-pregnant females may be indicative

of broader cross-neutralization **(Figure 2A-D).** This was reflected by reduced live virus

neutralizing antibody titers in pregnant compared with non-pregnant women to variants

(JN.1 p = 0.07, XBB.1.5 p = 0.03). Both cohorts showed a rise (p < 0.001) in neutralizing-

antibody titers to ancestral and BA.5 viruses after vaccination and were able to effectively

neutralize these viruses **(Figure 2E-F)**. Pregnant women, however, had significantly lower

nAb titers than non-pregnant females, with many pregnant women failing to reach the limit

of detection **(Figure 2G-H)**. In response to XBB.1.5, while vaccination significantly

increased nAb titers in both groups, these responses were significantly higher in non-

pregnant than pregnant females. Likewise, among non-pregnant females, vaccination

boosted nAb titers against JN.1; there was, however, no vaccine-induced increase in nAb

titers among pregnant women, with only 2/7 surpassing the limit of detection. **(Figure 2G-**

H). These data suggest that there is reduced breadth and cross-reactivity to variants after

COVID-19 boosting among pregnant compared with non-pregnant females.

Fc receptor affinity is not maintained in pregnant women against novel variants

While neutralizing-antibody titers are considered a correlate of protection for SARS-

CoV-2 infection [47], non-neutralizing functions also are important and may contribute to

robust protection from severe disease [48]. Data from mouse models suggest FcR-binding

affinity and its associated effector functions are necessary for preventing severe COVID-19

disease [49]. To further understand protection provided by mRNA boosters in pregnant

women, we investigated FcR binding affinity. Antibody Fc binding affinity to FcγRIIA-R,

FcγRIIA-H, FcγRIIb, FcγRIIIA-V, FcγRIIIA-F, FcγRIIIB, FcRn, and FcαR was assessed by a

multiplexed Luminex bead assay. FcR-binding affinity was similarly induced by vaccination

in response to ancestral and BA.5 vaccine antigens among both non-pregnant and

pregnant females **(Figure 3A-B).** While non-pregnant females saw similar increases in FcR

affinity to non-vaccine antigens following vaccination, vaccination did not induce changes

in FcR affinity in pregnant women, with no increase in affinity to 4/6 FcγRs in response to

XBB1.5 and 2/6 FcγRs in response to JN.1 (**Figure 3C-D**).

Non-neutralizing antibody functions and nAb are negatively correlated among

pregnant women

In order to understand how Fc-binding affinity contributes to immunity generated by

COVID-19 vaccination, several non-neutralizing antibody functions were assessed. Non-

neutralizing functions aid in the clearance of infected cells through recruiting effector cells

[50]. Antibody-dependent complement deposition (ADCD) was analyzed with a

multiplexed Luminex bead assay to measure antibody binding to complement protein C3

as a broad indicator of the ability of serum antibody to induce activation of the

complement cascade [40]. ADCD was induced by vaccination in both cohorts in response

to only XBB.1.5. (**Figure 4A**). As ADCD to ancestral and BA.5 S was high in pre-vaccination

samples, it is likely that there were high preexisting immune responses through

complement activation in both cohorts.

In pregnancy, macrophage inflammatory protein (MIP)-1β+ NK cells are found at the

maternal-fetal interface and are important for successful implantation and placentation

[51]. In NK cells, MIP-1β acts as a chemoattractant in response to activation [52]. Antibody-

dependent NK-cell cytotoxicity (ADNK) can be measured through MIP-1β production by NK

cells [53]. MIP-1β+ NK cells were uniquely elevated in pregnant women following

vaccination when compared with non-pregnant females (**Figure 4B**). In NK cells, interferon

gamma (IFNγ) acts as an antiviral cytokine to promote further accumulation, activation,

and cytotoxicity of NK cells [54]. As an additional readout of ADNK, NK cell IFNγ production

post-vaccination was elevated in pregnant women in response to BA.5 S and in non-

pregnant females in response to JN.1 S **(Supplemental Figure 2A).** There were no changes

post-vaccination in NK-cell degranulation, as marked by CD107a+ NK cells, among either

cohort **(Supplemental Figure 2B)**.

Antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent

neutrophil phagocytosis (ADNP) assess the ability of antibody to induce macrophage and

neutrophil phagocytosis of antigen, respectively, and are reported as a PhagoScore [41],

representing both the function and number of beads phagocytosed. ADCP and ADNP

decreased following vaccination against vaccine and variant antigens (**Figure 4C-D**). This is

likely indicative of a shift towards neutralization and away from non-neutralizing cellular

functions, a phenomenon that has been documented in the context of repeat vaccination

and may be a result of immune imprinting mechanisms [55]. Correlation analyses revealed

significant negative correlations between nAb titers and ADNP PhagoScores among

pregnant women only, further suggesting a shift away from neutralization, and towards

non-neutralizing neutrophil phagocytosis among pregnant women (**Figure 4E-H**). In non-

pregnant females, correlations were not significant, suggesting antibody responses marked

by both cellular non-neutralizing and neutralizing-antibody function, indicative of a more

comprehensive and multi-pronged immune response generated by vaccination.

Altered correlations among IgG subclasses and antibody functional phenotypes in

pregnant women

Correlation matrices can be used to examine complex relationships between

antibody isotypes and effector functions assessed by systems serology [56]. These

analyses can highlight isotype dependence and may reveal differences in subclass

functionality [56]. Spearman correlation matrices were generated to assess correlations

between Ig isotypes and FcR affinity and antibody functional properties post-vaccination in

response to vaccine and variant viruses (**Figure 5**). Matrices were most different between

pregnant and non-pregnant women for variants, with fewer strong correlations in pregnant

than non-pregnant women. Among non-pregnant women, IgG1 was positively and IgG3

was negatively correlated with FcR binding as well as neutralizing and non-neutralizing

antibody functions, particularly against variants. This trend was reversed in pregnant

women, with positive trends with IgG3 and negative trends with IgG1. These data further

implicate the reduced IgG1:IgG3 ratio and isotype subclass switching as functionally

altering antibody-mediated immunity in pregnant women.

Decreased polyfunctional CD4+ T cells responses in pregnant women

Because immunoglobulin subtype switching depends on CD4+ T-cell help and

cytokine production [57], we hypothesized that differences in CD4+ T-cell cytokine

production between pregnant and nonpregnant females might contribute to differences in

isotype switching and IgG subtypes. We assessed intracellular-cytokine production by

CD4+ T cells in pregnant and non-pregnant women in response to ancestral S-peptide

pools [58, 59]. Intracellular cytokine staining of CD4+ T cells in response to ancestral S-

peptide stimulation at post-vaccination timepoints demonstrated IFNγ+ monofunctional

dominance in pregnant women, represented by an expansion of the dark purple slice

(**Figure 6A**). In CD4+ T cells, IFNγ production is known to modulate class switching in B

cells, particularly favoring IgG3 over IgG1 [60-62]. Conversely, non-pregnant female

participants demonstrated more broadly polyfunctional CD4+ T-cell responses, defined as

producing two or more cytokines and highlighted by the arcs (**Figure 6B**). A greater

proportion of polyfunctional CD4+ T cells in the non-pregnant females were IL-21+,

represented by the green arc (**Figure 6B**). IL-21 is a cytokine that induces B cells to

differentiate into antibody-secreting cells [63] and has been linked to improved antibody

responses to vaccination [58, 64-66]. Polyfunctional CD4+ T-cell responses can enhance

nAb titers and immunity following vaccination against multiple pathogens, including SARS-

CoV-2 [67-69].

Polymorphonuclear myeloid-derived suppressor cells are increased during pregnancy

Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) have

previously been studied in the context of pregnancy, as they are required to maintain

maternal-fetal tolerance and are critical for fetal development [70, 71]. Their role, however,

has not been defined in the context of vaccination during pregnancy. There were no

detectable PMN-MDSCs in nonpregnant women, whereas the percentage in pregnant

women ranged from 0 to 1.5% of live PBMCs (**Supplemental Figure 3A**). The percentage of

low-density neutrophils also tended to be greater in pregnant women (**Supplemental**

Figure 3B), but small sample sizes preclude deeper analysis. The percentages of both

PMN-MDSCs and neutrophils were negatively correlated with CD4+ T cell cytokine

production in pregnant women (**Supplemental Figure 3C**).

Discussion

Through broad characterization of the antibody landscape following COVID-19

vaccination, pregnancy was associated with reduced cross-reactive ntibody responses,

reflected in decreased IgG1:IgG3 ratios, nAb titers, and FcR-binding affinity in pregnant

compared with non-pregnant women. Previous studies have assessed the antibody profile

generated by COVID-19 vaccination during pregnancy [28, 31, 72], with a focus on

transplacental antibody transfer and protection of babies and infants from severe disease.

One study showed limited cross-recognition in pregnant women to non-vaccine antigens

after the first doses of ancestral vaccines, with no comparisons with non-pregnant controls

[28]. Our data illustrate that pregnancy is associated with reduced isotype class switching

and lower nAb responses to variants as compared with non-pregnant controls. Continuing

efforts to assess antibody responses to updated vaccines remains critical to

understanding cross-protection to variants in circulation.

SARS-CoV-2 has continued to rapidly evolve and mutate into new variants to escape

adaptive-immune responses [73]. In 2022, Omicron variants became dominant in

circulation, largely due to an ability to evade nAb generated by ancestral vaccines and

natural infections [74]. New variants with the ability to evade nAb continue to emerge and

dominate, with XBB.1.5. appearing in October 2022 and peaking in January of 2023, after

the inclusion of BA.5 in bivalent booster vaccines was established [75]. By the time XBB.1.5

monovalent boosters were accessible, a new variant, JN.1 caused 60% of global cases [75,

76]. A potential limitation of annual vaccines is mismatches between dominate circulating

strains and updated booster vaccines because variants continue to emerge between

annual vaccines strain updates [11, 77, 78]. While mRNA technology has increased the

speed in which companies can adapt updated vaccines to emerging variants, development

of a new booster vaccine still takes several months [79]. Thus, government officials and

researchers must work collaboratively to select strains for booster vaccines that will elicit

the greatest breadth of immunity [79]. In our study, almost all women were vaccinated

against ancestral and BA.5 (bivalent boosters), while XBB.1.5. was the dominant variant in

circulation. Our data provide mechanistic evidence that pregnant women have limited

cross-protective antibodies.

With repeated exposure to antigen through natural infection and booster vaccines,

antibody responses to COVID-19 vaccines have evolved and correlates of protection have

changed. Total IgG and nAb titers are considered adequate correlates of protection against

COVID-19, similar to other acute respiratory infectious diseases [80]. Recent data have

suggested that to mount sufficient protection, antibodies against SARS-CoV-2 must

possess both neutralizing and non-neutralizing functions as correlates of protection [81].

As nAb titers wane and symptomatic cases rise, hospitalization rates among the general

population remain low [82]. This provides evidence that other antibody characteristics may

be important for protection from severe disease. Our data demonstrate that pregnant

women have reduced FcR binding and nAb responses combined with elevated ADNK and

ADNP, especially to non-vaccine antigens.

Our data suggest that reduced class switching and T-cell polyfunctionality may

contribute to limited cross-reactivity of antibodies during pregnancy. There is trend for

PMN-MDSCs in PBMCs to be more frequent among pregnant than non-pregnant, which

might contribute to suppressed CD4+ T cell cytokine production and proliferation [36].

CD4+ T cells are critical for generation of high affinity, class switched antibodies and

contribute to vaccine-induced protection against COVID-19 [83]. IL-21+ CD4+ T cells are

correlated with enhanced vaccine responses, including COVID-19 vaccine responses [65].

Pregnant women showed reduced expansion of IL-21+ CD4+ T cells, potentially

contributing to reduced Ig class switching and the generation of nAb responses in pregnant

women [58, 64-66]. Additionally, expansion of IFNγ+ monofunctional CD4+ T cells may

further contribute to reduced IgG1:IgG3 ratios among pregnant women, as these cells

promote IgG3 bias in B cells [60-62].

The small sample size is a limitation of this study and was associated with challenges

recruiting pregnant women. Previous studies have shown the impact of trimester on

immune responses generated by COVID-19 vaccination [17, 84]. In the present study,

sample size limited our ability to assess trimester differences, with 6/7 pregnant females

enrolled in our study being vaccinated in the second trimester of pregnancy. While 232

pregnant women were approached during the study enrollment window, only 7 completed

the study. This likely reflects the limited COVID-19 vaccine uptake among pregnant women,

which we show is caused by numerous factors across the care continuum that contribute

to COVID-19 vaccine hesitancy in this population. Identification of points of public-health

intervention to effectively increase vaccine uptake among pregnant women is needed.

Acknowledgements. We thank the clinical coordinators and vaccinees for making this

study possible. We are especially grateful to Kimberly Jones-Beatty and Michelle Ufua for

their assistance with recruitment. Thank you to Galit Alter, Ryan McNamara, and Taras

Chicz for graciously training lab members and sharing protocols to develop systems

serology methods. We thank Prakash Srinivasan for the use of the Attune Nxt flow

cytometer.

Funding. This study was supported by the Food and Drug Administration (FDA) of the U.S.

Department of Health and Human Services (HHS) as part of a financial assistance award

[Center of Excellence in Regulatory Science and Innovation grant to Johns Hopkins

University, U01FD005946] totaling $415,256 with 75% percentage funded by FDA/ OWH.

The contents are those of the author(s) and do not necessarily represent the official views

of, nor an endorsement, by FDA/OWH, or the U.S. Government. FDA CERSI U01FD005942

(SLK), NIH NIAID 75N93021C00045 (AP, RR), NIH NCI U54 CA260492 (SLK, ALC).

Data Availability

All anonymized data that support the findings of this study can be made available upon

reasonable request.

Author Contributions

SLK, IB, AP, and ALC conceptualized the experimental design and group comparisons for

this study. MAP, H-SP, JSL, LStC, PS, IB, JS, KF, RR, and ALC identified, acquired, stored, and

distributed patient samples and clinical and demographic data for analyses. MAP, H-SP,

PC, AW and JSL developed and validated serological assays. MAP, JS, LG and H-SP

processed samples and completed technical assays. MAP, KR, and AY conducted

statistical analyses. MAP, LG, KR, ALC, and SLK developed all tables and figures. MAP, ALC,

SLK wrote the initial draft of the manuscript. All authors provided substantive edits and

approved the final draft of the manuscript.

References
497

1.   Engjom, H.M., et al., *Perinatal outcomes after admission with COVID-19 in*
pregnancy: a UK national cohort study. Nature Communications, 2024. **15**(1): p.
3234.
2.   Brioschi Dos Santos, A.P., et al., *The impact of COVID-19 on maternal death and*
fetal death, a cohort study in Brazil. PLoS One, 2023. **18**(8): p. e0290343.
3.   St Clair, L.A., et al., *Reduced control of SARS-CoV-2 infection associates with lower*
mucosal antibody responses in pregnancy. mSphere, 2024. **9**(3): p. e0081223.
4.   Strid, P., et al., *Coronavirus Disease 2019 (COVID-19) Severity Among Women of*
Reproductive Age With Symptomatic Laboratory-Confirmed Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Pregnancy Status-
United States, 1 January 2020-25 December 2021. Clin Infect Dis, 2022. **75**(Suppl 2):
p. S317-s325.
5.   Wei, S.Q., et al., *The impact of COVID-19 on pregnancy outcomes: a systematic*
review and meta-analysis. Cmaj, 2021. **193**(16): p. E540-e548.

6.   Sessa, R., et al., *SARS-CoV-2 Infection in Pregnancy: Clues and Proof of Adverse*
513   *Outcomes.* Int J Environ Res Public Health, 2023. **20**(3).
514   7.   Garcia-Flores, V., et al., *Maternal-fetal immune responses in pregnant women*
515   *infected with SARS-CoV-2.* Nat Commun, 2022. **13**(1): p. 320.
516   8.   Verma, S., E.B. Carter, and I.U. Mysorekar, *SARS-CoV2 and pregnancy: An invisible*
517   *enemy?* Am J Reprod Immunol, 2020. **84**(5): p. e13308.
518   9.   Doss, J.D., et al., *A prospective cohort study of pregnancy outcomes following*
519   *antepartum infection with SARS-CoV-2.* Pregnancy Hypertens, 2024. **37**: p. 101152.
520   10.   Creisher, P.S., et al., *Adverse outcomes in SARS-CoV-2-infected pregnant mice are*
521   *gestational age-dependent and resolve with antiviral treatment.* J Clin Invest, 2023.
522   **133**(20).
523   11.   CDC. *Staying Up to Date with COVID-19 Vaccines*. 2025 January 7, 2025 [cited 2025
524   March 25]; Available from: https://www.cdc.gov/covid/vaccines/stay-up-to-
525   date.html.
526   12.   Ciapponi, A., et al., *Safety of COVID-19 vaccines during pregnancy: A systematic*
527   *review and meta-analysis*. Vaccine, 2023. **41**(25): p. 3688-3700.
528   13.   Razzaghi, H., et al., *COVID-19 vaccination coverage and intent among women aged*
529   *18-49 years by pregnancy status, United States, April-November 2021*. Vaccine,
530   2022. **40**(32): p. 4554-4563.
531   14.   CDC. *COVID-19 Vaccination Coverage, Pregnant Women, United States*. 2025
532   March 19 [cited 2025; Available from: https://www.cdc.gov/covidvaxview/weekly-
533   dashboard/pregnant-persons-vaccination.html.
534   15.   Razzaghi H, K.K., Calhoun K, et al., *Influenza, Tdap, and COVID-19 Vaccination*
535   *Coverage and Hesitancy Among Pregnant Women — United States, April 2023*.
536   MMWR Morb Mortal Wkly Rep, 2023.
537   16.   Katherine E. Kahn, E.G., Hilda Razzaghi, Tara C. Jatlaoui, Tami H. Skoff, Sascha R.
538   Ellington, Carla L. Black, *Flu, Tdap, and COVID-19 Vaccination Coverage Among*
539   *Pregnant Women – United States, April 2024*. 2024.
540   17.   Norman, M., et al., *Neonatal Outcomes After COVID-19 Vaccination in Pregnancy*.
541   Jama, 2024. **331**(5): p. 396-407.
542   18.   CDC. *COVID-19 Vaccination for Women Who Are Pregnant or Breastfeeding*. 2024
543   September 10, 2024; Available from:
544   https://www.cdc.gov/covid/vaccines/pregnant-or-
545   breastfeeding.html#:~:text=COVID%2D19%20vaccination%20during%20pregnancy
546   ,19%20before%20or%20during%20pregnancy.
547   19.   Kumar, D., S. Verma, and I.U. Mysorekar, *COVID-19 and pregnancy: clinical*
548   *outcomes; mechanisms, and vaccine efficacy*. Transl Res, 2023. **251**: p. 84-95.
549   20.   Casubhoy, I., et al., *A scoping review of global COVID-19 vaccine hesitancy among*
550   *pregnant persons*. npj Vaccines, 2024. **9**(1): p. 131.
551   21.   Oliver, J., et al., *Drivers of COVID-19 vaccine hesitancy among women of*
552   *childbearing age in Victoria, Australia: A descriptive qualitative study*. Vaccine: X,
553   2022. **12**: p. 100240.
554   22.   Hsu, A.L., et al., *Sources of Vaccine Hesitancy: Pregnancy, Infertility, Minority*
555   *Concerns, and General Skepticism*. Open Forum Infectious Diseases, 2021. **9**(3).

23. Shephard HM, M.S., Nestoridi E, et al. *Inequities in COVID-19 Vaccination Coverage*
Among Pregnant Persons. MMWR Morb Mortal Wkly Rep 2023 September 29, 2023.
24. Anderson, M.R., E.J. Hardy, and C.L. Battle, *COVID-19 Vaccine Hesitancy during the*
Perinatal Period: Understanding Psychological and Cultural Factors to Improve Care
and Address Racial/Ethnic Health Inequities. Womens Health Issues, 2022. **32**(4): p.
317-321.
25. Ramonfaur, D., et al., *Determinants of COVID-19 vaccine hesitancy among pregnant*
persons. J Am Pharm Assoc (2003), 2023. **63**(4): p. 1191-1196.
26. Chavan, M., et al., *COVID-19 Vaccination in Pregnancy: The Benefits Outweigh the*
Risks. J Obstet Gynaecol Can, 2021. **43**(7): p. 814-816.
27. Kay, A.W. and C.A. Blish, *Immunogenicity and Clinical Efficacy of Influenza*
Vaccination in Pregnancy. Front Immunol, 2015. **6**: p. 289.
28. Lopez, P.A., et al., *Placental transfer dynamics and durability of maternal COVID-19*
vaccine-induced antibodies in infants. iScience, 2024. **27**(3): p. 109273.
29. Munoz, F.M., et al., *COVID-19 booster vaccination during pregnancy enhances*
maternal binding and neutralizing antibody responses and transplacental antibody
transfer to the newborn. Vaccine, 2023. **41**(36): p. 5296-5303.
30. Cassidy, A.G., et al., *Assessment of Adverse Reactions, Antibody Patterns, and 12-*
month Outcomes in the Mother-Infant Dyad After COVID-19 mRNA Vaccination in
Pregnancy. JAMA Netw Open, 2023. **6**(7): p. e2323405.
31. Atyeo, C., et al., *COVID-19 mRNA vaccines drive differential antibody Fc-functional*
profiles in pregnant, lactating, and nonpregnant women. Sci Transl Med, 2021.
13(617): p. eabi8631.
32. Ackerman, M.E., D.H. Barouch, and G. Alter, *Systems serology for evaluation of HIV*
vaccine trials. Immunol Rev, 2017. **275**(1): p. 262-270.
33. Fall, A., et al., *The displacement of the SARS-CoV-2 variant Delta with Omicron: An*
investigation of hospital admissions and upper respiratory viral loads. EBioMedicine,
2022. **79**: p. 104008.
34. Dhakal, S., et al., *Sex Differences in Lung Imaging and SARS-CoV-2 Antibody*
Responses in a COVID-19 Golden Syrian Hamster Model. mBio, 2021. **12**(4): p.
e0097421.
35. Dhakal, S., et al., *Reconsideration of Antinucleocapsid IgG Antibody as a Marker of*
SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients. Open Forum
Infect Dis, 2023. **10**(1): p. ofac677.
36. Lee, J.M., et al., *Three doses of COVID-19 mRNA vaccine induce class-switched*
antibody responses in inflammatory arthritis patients on immunomodulatory
therapies. Front Immunol, 2023. **14**: p. 1266370.
37. Li, M., et al., *Convalescent plasma with a high level of virus-specific antibody*
effectively neutralizes SARS-CoV-2 variants of concern. Blood Adv, 2022. **6**(12): p.
3678-3683.
38. Klein, S.L., et al., *Sex, age, and hospitalization drive antibody responses in a COVID-*
19 convalescent plasma donor population. J Clin Invest, 2020. **130**(11): p. 6141-
6150.

39.   Karger, A.B., et al., *The Serological Sciences Network (SeroNet) for COVID-19: Depth*
600   *and Breadth of Serology Assays and Plans for Assay Harmonization*. mSphere, 2022.
601   **7**(4): p. e0019322.
602   40.   Chung, A.W., et al., *Dissecting Polyclonal Vaccine-Induced Humoral Immunity*
603   *against HIV Using Systems Serology*. Cell, 2015. **163**(4): p. 988-98.
604   41.   Karsten, C.B., et al., *A versatile high-throughput assay to characterize antibody-*
605   *mediated neutrophil phagocytosis*. J Immunol Methods, 2019. **471**: p. 46-56.
606   42.   Loos, C., et al., *Systems serology-based comparison of antibody effector functions*
607   *induced by adjuvanted vaccines to guide vaccine design*. npj Vaccines, 2023. **8**(1): p.
608   34.
609   43.   Kolde, R., *Pretty Heatmaps*. 2018. p. Implementation of heatmaps that offers more
610   control over dimensions and appearance.
611   44.   Gaeta, A., et al., *Anti-N SARS-CoV-2 assays for evaluation of natural viral infection*. J
612   Immunol Methods, 2023. **518**: p. 113486.
613   45.   Swadźba, J., et al., *High Concentration of Anti-SARS-CoV-2 Antibodies 2 Years after*
614   *COVID-19 Vaccination Stems Not Only from Boosters but Also from Widespread,*
615   *Often Unrecognized, Contact with the Virus*. Vaccines (Basel), 2024. **12**(5).
616   46.   Chen, W., et al., *The kinetics of IgG subclasses and contributions to neutralizing*
617   *activity against SARS-CoV-2 wild-type strain and variants in healthy adults*
618   *immunized with inactivated vaccine*. Immunology, 2022. **167**(2): p. 221-232.
619   47.   Sun, K., et al., *SARS-CoV-2 correlates of protection from infection against variants of*
620   *concern*. Nature Medicine, 2024. **30**(10): p. 2805-2812.
621   48.   Izadi, A. and P. Nordenfelt, *Protective non-neutralizing SARS-CoV-2 monoclonal*
622   *antibodies*. Trends Immunol, 2024. **45**(8): p. 609-624.
623   49.   Mackin, S.R., et al., *Fc-γR-dependent antibody effector functions are required for*
624   *vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2*. Nat
625   Microbiol, 2023. **8**(4): p. 569-580.
626   50.   Chandler, T.L., et al., *Protective mechanisms of nonneutralizing antiviral antibodies*.
627   PLoS Pathog, 2023. **19**(10): p. e1011670.
628   51.   Du, M.R., S.C. Wang, and D.J. Li, *The integrative roles of chemokines at the*
629   *maternal-fetal interface in early pregnancy*. Cell Mol Immunol, 2014. **11**(5): p. 438-
630   48.
631   52.   Bluman, E.M., et al., *Human natural killer cells produce abundant macrophage*
632   *inflammatory protein-1 alpha in response to monocyte-derived cytokines*. J Clin
633   Invest, 1996. **97**(12): p. 2722-7.
634   53.   Boudreau, C.M., et al., *Antibody-mediated NK cell activation as a correlate of*
635   *immunity against influenza infection*. Nature Communications, 2023. **14**(1): p. 5170.
636   54.   Lin, Q., et al., *IFN-γ-dependent NK cell activation is essential to metastasis*
637   *suppression by engineered Salmonella*. Nature Communications, 2021. **12**(1): p.
638   2537.
639   55.   Tortorici, M.A., et al., *Persistent immune imprinting occurs after vaccination with the*
640   *COVID-19 XBB.1.5 mRNA booster in humans*. Immunity, 2024. **57**(4): p. 904-911.e4.
641   56.   Atyeo, C., et al., *Distinct Early Serological Signatures Track with SARS-CoV-2*
642   *Survival*. Immunity, 2020. **53**(3): p. 524-532.e4.

643   57.   Sha, Z. and R.W. Compans, *Induction of CD4(+) T-cell-independent immunoglobulin*
644   *responses by inactivated influenza virus.* J Virol, 2000. **74**(11): p. 4999-5005.
645   58.   Thompson, E.A., et al., *Heterologous versus homologous boosting elicits*
646   *qualitatively distinct, BA.5-cross-reactive T cells in transplant recipients.* JCI Insight,
647   2023. **8**(10).
648   59.   Roznik, K., et al., *COVID-19 vaccination induces distinct T-cell responses in*
649   *pediatric solid organ transplant recipients and immunocompetent children.* NPJ
650   Vaccines, 2024. **9**(1): p. 73.
651   60.   Peng, S.L., S.J. Szabo, and L.H. Glimcher, *T-bet regulates IgG class switching and*
652   *pathogenic autoantibody production.* Proc Natl Acad Sci U S A, 2002. **99**(8): p. 5545-
653   50.
654   61.   Alspach, E., D.M. Lussier, and R.D. Schreiber, *Interferon γ and Its Important Roles in*
655   *Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.* Cold
656   Spring Harb Perspect Biol, 2019. **11**(3).
657   62.   Mohr, E., et al., *IFN-{gamma} produced by CD8 T cells induces T-bet-dependent and*
658   *-independent class switching in B cells in responses to alum-precipitated protein*
659   *vaccine.* Proc Natl Acad Sci U S A, 2010. **107**(40): p. 17292-7.
660   63.   Wang, S., et al., *IL-21 drives expansion and plasma cell differentiation of*
661   *autoreactive CD11chiT-bet+ B cells in SLE.* Nature Communications, 2018. **9**(1): p.
662   1758.
663   64.   Pallikkuth, S., et al., *Upregulation of IL-21 receptor on B cells and IL-21 secretion*
664   *distinguishes novel 2009 H1N1 vaccine responders from nonresponders among*
665   *HIV-infected persons on combination antiretroviral therapy.* J Immunol, 2011.
666   **186**(11): p. 6173-81.
667   65.   Malahe, S.R.K., et al., *The role of interleukin-21 in COVID-19 vaccine-induced B cell-*
668   *mediated immune responses in patients with kidney disease and kidney transplant*
669   *recipients.* Am J Transplant, 2023. **23**(9): p. 1411-1424.
670   66.   Fan, W., Y. Wan, and Q. Li, *Interleukin-21 enhances the antibody avidity elicited by*
671   *DNA prime and MVA boost vaccine.* Cytokine, 2020. **125**: p. 154814.
672   67.   Darrah, P.A., et al., *Multifunctional TH1 cells define a correlate of vaccine-mediated*
673   *protection against Leishmania major.* Nat Med, 2007. **13**(7): p. 843-50.
674   68.   Rakshit, S., et al., *Polyfunctional CD4 T-cells correlating with neutralising antibody is*
675   *a hallmark of COVISHIELDTM and COVAXIN® induced immunity in COVID-19*
676   *exposed Indians.* npj Vaccines, 2023. **8**(1): p. 134.
677   69.   Li, L., et al., *In-depth analysis of SARS-CoV-2-specific T cells reveals diverse*
678   *differentiation hierarchies in vaccinated individuals.* JCI Insight, 2022. **7**(7).
679   70.   Shi, M., et al., *Continuous activation of polymorphonuclear myeloid-derived*
680   *suppressor cells during pregnancy is critical for fetal development.* Cellular &
681   Molecular Immunology, 2021. **18**(7): p. 1692-1707.
682   71.   Li, C., et al., *Upregulated TRAIL and Reduced DcR2 Mediate Apoptosis of Decidual*
683   *PMN-MDSC in Unexplained Recurrent Pregnancy Loss.* Frontiers in Immunology,
684   2020. **11**.

72.   Atyeo, C.G., et al., *Maternal immune response and placental antibody transfer after*
COVID-19 vaccination across trimester and platforms. Nature Communications,
2022. **13**(1): p. 3571.
73.   Markov, P.V., et al., *The evolution of SARS-CoV-2.* Nature Reviews Microbiology,
2023. **21**(6): p. 361-379.
74.   Chi, W.Y., et al., *COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2*
variants, boosters, adverse effects, and immune correlates of protection. J Biomed
Sci, 2022. **29**(1): p. 82.
75.   Huiberts, A.J., et al., *Effectiveness of Omicron XBB.1.5 vaccine against infection*
with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the
Netherlands, October 2023 to January 2024. Euro Surveill, 2024. **29**(10).
76.   Rubin, R., *As COVID-19 Cases Surge, Here's What to Know About JN.1, the Latest*
SARS-CoV-2 "Variant of Interest". Jama, 2024. **331**(5): p. 382-383.
77.   Han, X. and Q. Ye, *The variants of SARS-CoV-2 and the challenges of vaccines.* J Med
Virol, 2022. **94**(4): p. 1366-1372.
78.   Cobey, S., et al., *Concerns about SARS-CoV-2 evolution should not hold back efforts*
to expand vaccination. Nat Rev Immunol, 2021. **21**(5): p. 330-335.
79.   Monto, A.S., A.S. Lauring, and E.T. Martin, *SARS-CoV-2 Vaccine Strain Selection:*
Guidance From Influenza. J Infect Dis, 2022. **227**(1): p. 4-8.
80.   Regev-Yochay, G., et al., *Correlates of protection against COVID-19 infection and*
intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2
in households in Israel (ICoFS): a prospective cohort study. The Lancet Microbe,
2023. **4**(5): p. e309-e318.
81.   Goldblatt, D., et al., *Correlates of protection against SARS-CoV-2 infection and*
COVID-19 disease. Immunol Rev, 2022. **310**(1): p. 6-26.
82.   Mahrokhian, S.H., et al., *COVID-19 vaccines: Immune correlates and clinical*
outcomes. Hum Vaccin Immunother, 2024. **20**(1): p. 2324549.
83.   Kent, S.J., et al., *Disentangling the relative importance of T cell responses in COVID-*
19: leading actors or supporting cast? Nature Reviews Immunology, 2022. **22**(6): p.
387-397.
84.   Yang, Y.J., et al., *Association of Gestational Age at Coronavirus Disease 2019*
(COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus
2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical
Cord Antibody Levels at Delivery. Obstetrics & Gynecology, 2022. **139**(3): p. 373-380.
719

Graphical abstract

Table 1: Study Demographics

	Non-Pregnant n = 13		Pregnant n = 7		P-Value
Demographics	Mean $\pm$ SD		Mean $\pm$ SD		
Age	33.1 $\pm$ 6.1		32.9 $\pm$3.2		0.93064
Vaccine Type					
Monovalent Booster	0	0%	2	28.5%	
Bivalent Booster	10	100%	5	71.5%	
Average Gestational					
Age (weeks)	-		22.4 $\pm$ 11.78		
	N	%	N	%	
Race					
White	8	61.5%	7	100%	
Black	2	15.4%	0	0%	
Asian	3	23.1%	0	0%	
Gestational Age (At Vaccination)	-		1st Trimester (n = 0) 0% 2nd Trimester (n = 6) 85.8% 3rd Trimester (n = 1) 14.2%		

Table 1.

Figure 1. Vaccination differently induces IgG subtype responses during pregnancy. IgG antibody responses in serum pre and 3-5 weeks post-vaccination were measured by systems serology and reported as $\log_{10}$ mean fluorescence intensity (MFI). Pregnant individuals (n=7) are shown in orange and non-pregnant females (n=13) in purple. Triangles highlight individuals who received monovalent boosters and circles represent bivalent booster recipients. **(A)** Total IgG to ancestral nucleocapsid (N) protein. **(B)** Total IgG separated by SARS-CoV-2 vaccine (ancestral and BA.5) and variant (XBB1.5 and JN.1) spike (S) antigen and pregnancy status. **(C-F)** Relative abundance of IgG subtypes in pregnant and non-pregnant people as stacked bar plots representing each isotype as a percentage of Total IgG by **(C)** ancestral S, **(D)** BA.5 S, **(E)** XBB.1.5 S, and **(F)** JN.1 S. Data were analyzed by **(A)** repeated measures two-way ANOVA **(B-F)** linear mixed effects regression analysis with Bonferroni post-hoc. Asterisks indicate p< 0.05. Stippled line indicates limit of background (LOB) defined as the $\log_{10}$MFI of a defined negative control.

Figure 2. Pregnancy alters cross-neutralization of variants of concern. IgG antibody responses in serum pre and 3-5 weeks post-vaccination were measured by systems serology and reported as mean fluorescence intensity (MFI). Pregnant individuals (n=7) are shown in orange and non-pregnant females (n=13) in purple. Triangles highlight individuals who received monovalent boosters and circles represent bivalent booster recipients. **(A-E)** Ratio of IgG1:IgG3 antibodies specific to **(A)** ancestral spike (S), **(B)** BA.5 S, **(C)** XBB.1.5 S, and **(D)** JN.1 S. Neutralizing antibody (nAb) titers reported as Log$_2$ NT50 against live **(E)** ancestral, **(F)** BA.5, **(G)** XBB.1.5, and **(H)** JN.1 viruses. Ratios indicate number of individuals above the limit of detection (LOD) indicated by the stippled line. Data were analyzed by repeated measures two-way ANOVA with Bonferroni post-hoc. Asterisks indicate p< 0.05.

Figure 3. Fc receptor binding affinity is reduced in pregnant people in response to variants of concern. Serum antibody Fc receptor (FcR) binding affinity pre and 3-5 weeks post-vaccination were measured by multiplex Luminex bead assays and reported as $\log_{10}$ mean fluorescence intensity (MFI). Pregnant individuals (n=7) are shown in orange and non-pregnant females (n=13) in purple. Triangles highlight individuals who received monovalent boosters and circles represent bivalent booster recipients. Affinity for FcγRIIA-R, FcγRIIA-H, FcγRIIb, FcγRIIIA-V, FcγRIIIA-F, FcγRIIIB, FcRn, and FcαR was determined for **(A)** ancestral spike (S), **(B)** BA.5 S, **(C)** XBB.1.5 S, and **(D)** JN.1 S. Data were analyzed by linear mixed effects regression analysis with Bonferroni post-hoc. Asterisks indicate $p < 0.05$. Stippled line indicates limit of background (LOB) defined as the $\log_{10}$MFI of a defined negative control.

Figure 4. Non-neutralizing and neutralizing antibody functions are negatively correlated among pregnant individuals. Non-neutralizing antibody functions were measured pre and 3-5 weeks post-vaccination. Pregnant individuals (n=7) are shown in orange and non-pregnant females (n=13) in purple. Triangles highlight individuals who received monovalent boosters and circles represent bivalent booster recipients. **(A)** antibody dependent complement deposition (ADCD) was measured by assessing antibody affinity for C3 protein and is reported as $\log_{10}$ mean fluorescence intensity (MFI). Stippled line indicates limit of background (LOB) defined as the $\log_{10}$MFI of a defined negative control. NK cells isolated from donor blood were utilized to assess **(B)** antibody dependent NK cell cytotoxicity (ADNK), or the ability of antigen specific serum antibody to include NK cell cytokine production or degranulation. Data are reported as % MIP1B+ cells of CD16+/CD56+ NK cells. **(C)** THP-1 monocyte cell line was used to measure antibody dependent cellular phagocytosis (ADCP), or the ability of antibody to induce phagocytosis of antigen. **(D)** Neutrophils isolated from donor blood were used to measure antibody dependent neutrophil phagocytosis (ADNP), or the ability of antibody to induce neutrophil phagocytosis of antigen. ADCP and ADNP are reported as a PhagoScore, calculated as (% bead positive monocytes/neutrophils) * (geometric MFI of each cell). **(E-H)** Pearson correlations between neutralizing antibody titers ($\log_2$NT50) and ADNP PhagoScores for are shown for: **(E)** ancestral, **(F)** BA.5, **(G)** XBB.1.5, and **(H)** JN.1 viruses. Separate R2 and p-values are shown for each virus separated by pregnancy status. **(A-E)** Data were analyzed by linear mixed effects regression analysis with Bonferroni post-hoc. Asterisks indicate $p < 0.05$.

Figure 5. Correlations among IgG subclasses and antibody functional phenotypes differ between pregnant and nonpregnant individuals. Post-vaccination systems serology measures including isotype subclasses, FcR affinity, non-neutralizing functions, and neutralizing antibody (nAb) titers were $\log_{10}$ transformed and used for Spearman correlation analyses. Isotypes (y-axis) were correlated with functional measures (x-axis). Analyses were performed by pregnancy status. Asterisks indicate $p < 0.05$.

Figure 6. CD4+ T cells have reduced polyfunctionality among pregnant people. Peripheral blood mononuclear cells (PBMCs) were collected pre and 3-5 weeks post-vaccination for flow cytometry analyses. Cytokine-producing, antigen-specific CD4+T cells for **(A)** pregnant (n=7) and **(B)** non-pregnant (n=3) participants represented in pie charts broken down by the 15 cytokine combination categories. Arcs identify slices of the pie that express each specific cytokine**.** R values are shown for each correlation, and asterisks indicate p< 0.05.

Supplemental Figure 1. Vaccination differently induces IgG subtype responses during pregnancy. IgG antibody responses in serum pre and 3-5 weeks post-vaccination were measured by systems serology and reported as log₁₀ mean fluorescence intensity (MFI). Pregnant individuals (n=7) are shown in orange and non-pregnant females (n=13) in purple. Triangles highlight individuals who received monovalent boosters and circles represent bivalent booster recipients. **(A)** IgG subtype abundance to ancestral nucleocapsid (N) protein. IgG subtypes, including **(B)** IgG1 **(C)** IgG2, **(D)** IgG3, and **(E)** IgG4, in response to ancestral, BA.5, XBB.1.5, and JN.1 spike protein. Data were analyzed by linear mixed effects regression analysis with Bonferroni post-hoc. Asterisks indicate p< 0.05.

Supplemental Figure 2. Additional antibody-dependent NK cell responses by pregnancy status. NK cells isolated from donor blood were utilized to assess antibody dependent NK cell cytotoxicity (ADNK), or the ability of antigen specific serum antibody to include NK cell cytokine production or degranulation in serum pre and 3-5 weeks post-vaccination. Pregnant individuals (n=7) are shown in orange and non-pregnant females (n=13) in purple. Triangles highlight individuals who received monovalent boosters and circles represent bivalent booster recipients. ADNK was measured as ability to induce **(A)** IFNy production or **(B)** NK cell degranulation, as measured by CD107a positivity. Data were analyzed by linear mixed effects regression analysis with Bonferroni post-hoc. Asterisks indicate p< 0.05.

Supplemental Figure 3. Polymorphonuclear myeloid-derived suppressor cells correlate with CD4+ cytokine producing cells. Peripheral blood mononuclear cells (PBMCs) were collected pre and 3-5 weeks post-vaccination for flow cytometry analyses. Pregnant individuals (n=7) are shown in orange and non-pregnant females (n=3) in purple. Triangles highlight individuals who received monovalent boosters and circles represent bivalent booster recipients. **(A)** Neutrophils and **(C)** polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) were quantified by flow cytometry and reported as a percentage of total live single cells. **(D)** Pearson correlations between cytokine producing CD4+ T cells, neutrophils, and PMN-MDSCs from pregnant people. R values are shown for each correlation, and asterisks indicate p< 0.05.

Supplemental Figure 4. PMN-MDSC gating strategy.

Supplemental Figure 5. Cytokine positive CD4+ T cells.

Supplemental Table 1A-B. Broad immune cell phenotyping (BIP) flow cytometry panel. (A) surface staining markers and **(B)** intracellular markers.

A. Surface

Fluorophore	Marker	Clone	Catalog	Vendor
BV570	CD33	WM53	303417	BioLegend
BV480	CD11c	B-ly6	566135	BD Biosciences
APC	CD123	6H6	306012	BioLegend
BV510	CD25	M-A251	563352	BD Biosciences
BV650	CCR7	G043H7	353234	BioLegend
BV421	LOX1	15C4	358610	BioLegend
BV711	CD38	HIT2	563965	BD Biosciences
APC-Cy7	CD19	SJ25C1	363010	BioLegend
APC-Cy7	CD56	5.1H11	362512	BioLegend
BV750	HLA-DR	L243	307672	BioLegend
BUV661	CD3	UCHT1	612964	BD Biosciences
BUV496	CD4	SK3	612936	BD Biosciences
BUV737	CD8	SK1	612754	BD Biosciences
BV785	CD16	3G8	302046	BioLegend
BUV805	CD14	M5E2	612902	BD Biosciences
BV605	CD86	BU63	374214	BioLegend
BUV563	CD45RA	HI100	612926	BD Biosciences
BUV395	CD15	H198	563872	BD Biosciences
Spark NIR	CD27	O232	302856	BioLegend
PE-Cy5	CD21	B-ly4	551064	BD Biosciences
PE-Cy5.5*	CD138	MI15	356502	BioLegend
PE-CF594	KLRG1	2F1	565393	BD Biosciences
BB790	IgD	IA6-2	BD Custom	BD Biosciences
BUV615	PD-1	EH12.1	612991	BD Biosciences

B. Intracellular

Fluorophore	Marker	Clone	Catalog	Vendor
Pacific Blue	FOXP3	206D	320116	BioLegend
PE-Cy7	Ki-67	Ki-67	350526	BioLegend
Alexa Fluor 488	CPT1a	8F6AE9	ab171449	Abcam
Alexa Fluor 680**	HK2	EPR20839	ab228819	Abcam
Alexa Fluor 532***	VDAC1	20B12AF2	ab14734	Abcam

Alexa Fluor 405	Tomm20	EPR15581-54	ab210047	Abcam
Alexa Fluor 647	GLUT1	EPR3915	ab195020	Abcam

Notes: * conjugated using PE/Cy5.5 Conjugation Kit - Lightning-Link (ab102899)

   ** conjugated using DyLight 680 Conjugation Kit (Fast) - Lightning-Link (ab201804)

   *** conjugated using Alexa Fluor 532 Antibody Labeling Kit (Thermo Fisher, A20182)

Supplemental Table 2. Intracellular cytokine staining (ICS) flow cytometry panel. (A) surface staining markers and **(B)** intracellular markers.

A. Surface

Fluorophore	Marker	Clone	Catalog	Vendor
BUV395	CCR7	2-L1-A	749655	BD Biosciences
BV650	CXCR3	1C6	740603	BD Biosciences
PE CF594	KLRG1	2F1	565393	BD Biosciences
BV605	CD69	FN50	562989	BD Biosciences
BUV563	CD25	2A3	612918	BD Biosciences
BUV661	PD-1	EH12.1	750260	BD Biosciences
BUV737	TIM-3	7D3	748820	BD Biosciences
BV570	CD28	CD28.2	302926	Biolegend
PE Cy5	CD127	HIL-7R-M21	BD Custom	BD Biosciences
BUV805	CD4	SK3	612887	BD Biosciences
APC H7	CD45RA	HI100	560674	BD Biosciences
BB660	Tigit	741182	BD Custom	BD Biosciences
BV711	OX40	ACT35	563664	BD Biosciences
BV786	CD27	L128	563327	BD Biosciences
PE Cy7	CTLA-4	BNI3	BD Custom	BD Biosciences
BV510	CD8a	HIT8a	300934	Biolegend
BB790	CXCR5	RF8B2	BD Custom	BD Biosciences

B. Intracellular

Fluorophore	Marker	Clone	Catalog	Vendor
PE	IL-21	3A3-N2	513004	BioLegend
AF680**	HK2	EPR20839	ab228819	Abcam
AF488	TCF1	812145	IC8224G	FisherScientific
BV421	IL-2	MQ1-17H12	564164	BD Biosciences
AF532***	VDAC1	20B12AF2	ab14734	Abcam

BV750	TNF	MAb11	566359	BD Biosciences
PECy5.5*	CPT1a	8F6AE9	ab128568	Abcam
AF405	Tomm20	EPR15581-54	ab210047	Abcam
Alexa647	GLUT1	EPR3915	ab195020	Abcam
BUV496	CD3	UCHT1	612940	BD Biosciences
BB700	IFNy	B27	566394	BD Biosciences

Notes: * conjugated using PE/Cy5.5 Conjugation Kit - Lightning-Link (ab102899)

** conjugated using DyLight 680 Conjugation Kit (Fast) - Lightning-Link (ab201804)

*** conjugated using Alexa Fluor 532 Antibody Labeling Kit (Thermo Fisher, A20182)